Should I buy or sell Medexus Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDP shares. View MDP analyst ratings or view top-rated stocks .

What is Medexus Pharmaceuticals' stock price target for 2024?

2 equities research analysts have issued 1 year price targets for Medexus Pharmaceuticals' stock. Their MDP share price targets range from C$2.35 to C$4.00. On average, they expect the company's stock price to reach C$3.18 in the next twelve months. This suggests that the stock has a possible downside of 59.0%. View analysts price targets for MDP or view top-rated stocks among Wall Street analysts .

How have MDP shares performed in 2024?

Medexus Pharmaceuticals' stock was trading at C$7.75 at the beginning of 2024. Since then, MDP shares have increased by 0.0% and is now trading at C$7.75. View the best growth stocks for 2024 here .

What other stocks do shareholders of Medexus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medexus Pharmaceuticals investors own include Gatekeeper Systems (GSI) , Enghouse Systems (ENGH) , Ag Growth International (AFN) .

How do I buy shares of Medexus Pharmaceuticals?

Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

CVE:MDP

Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free MDP Stock Alerts

C$7.75

-0.40 (-4.91%)

(As of 06/16/2021)

Compare

Today's Range: C$7.70
▼
C$8.14
50-Day Range: C$7.75
▼
C$7.75
52-Week Range: C$2.80
▼
C$9.75

Volume: 40,981 shs
Average Volume: 68,619 shs
Market Capitalization: C$148.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$3.18

Stock Analysis

Get Medexus Pharmaceuticals alerts:

Medexus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 59.0% Downside
C$3.18 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
C$5,408 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.06 out of 5 stars

1.5

Analyst's Opinion

Consensus Rating
Medexus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Medexus Pharmaceuticals has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for MDP.

0.0

Dividend Strength

Dividend Yield
Medexus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Medexus Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MDP.

0.6

News and Social Media Coverage

Search Interest
2 people have searched for MDP on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Medexus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$5,408.00 in company stock and sold C$0.00 in company stock.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Medexus Pharmaceuticals is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Medexus Pharmaceuticals is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Due to a projected decrease in earnings for Medexus Pharmaceuticals, their PEG ratio cannot be calculated.
Price to Book Value per Share Ratio
Medexus Pharmaceuticals has a P/B Ratio of 20.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Medexus Pharmaceuticals Stock (CVE:MDP)

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.

MDP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MDP Stock News Headlines

February 13, 2024 | au.finance.yahoo.com

Medexus Pharmaceuticals Inc (P731.BE)

February 10, 2024 | finance.yahoo.com

Medexus Pharmaceuticals Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

January 30, 2024 | finance.yahoo.com

Medexus Schedules Third Fiscal Quarter 2024 Conference Call

November 30, 2023 | finance.yahoo.com

Boasting A 23% Return On Equity, Is Medexus Pharmaceuticals Inc. (TSE:MDP) A Top Quality Stock?

November 8, 2023 | finance.yahoo.com

Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million

November 1, 2023 | finance.yahoo.com

Medexus Schedules Second Fiscal Quarter 2024 Conference Call

October 16, 2023 | finance.yahoo.com

Canadian Investment Regulatory Organization Trading Halt - MDP.DB

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

October 11, 2023 | finance.yahoo.com

Medexus Pharmaceuticals' (TSE:MDP) earnings growth rate lags the 131% return delivered to shareholders

October 6, 2023 | finance.yahoo.com

Medexus Announces Closing of C$10 Million Bought-Deal Public Offering

September 15, 2023 | finance.yahoo.com

Shareholders May Be More Conservative With Medexus Pharmaceuticals Inc.'s (TSE:MDP) CEO Compensation For Now

August 31, 2023 | msn.com

Medexus Pharmaceuticals (MEDXF) Price Target Increased by 16.36% to 3.18

August 23, 2023 | theglobeandmail.com

Closing Bell: Medexus Pharmaceuticals Inc up on Wednesday (MDP)

August 19, 2023 | finance.yahoo.com

Here's Why We Think Medexus Pharmaceuticals (TSE:MDP) Is Well Worth Watching

July 13, 2023 | markets.businessinsider.com

Medexus Pharmaceuticals Inc (MDP) Gets a Buy Rating from Stifel Nicolaus

June 22, 2023 | markets.businessinsider.com

Medexus Pharmaceuticals Inc (MDP) Receives a Buy from Echelon Wealth Partners

June 21, 2023 | finanznachrichten.de

Medexus Pharmaceuticals Inc.: Medexus Generates Record Revenue of Us$108.1 Million in Fiscal Year 2023

June 21, 2023 | finance.yahoo.com

Medexus Generates Record Revenue of US$108.1 Million in Fiscal Year 2023

June 13, 2023 | finance.yahoo.com

Medexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023

May 9, 2023 | finance.yahoo.com

Medexus Demonstrates Cost-Effectiveness of Gleolan-Guided Surgery for High-Grade Glioma

May 3, 2023 | theglobeandmail.com

Closing Bell: Medexus Pharmaceuticals Inc down on Tuesday (MDP)

April 18, 2023 | finance.yahoo.com

Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 14, 2023 | theglobeandmail.com

Closing Bell: Medexus Pharmaceuticals Inc down on Thursday (MDP)

April 13, 2023 | theglobeandmail.com

Closing Bell: Medexus Pharmaceuticals Inc down on Wednesday (MDP)

April 12, 2023 | theglobeandmail.com

Closing Bell: Medexus Pharmaceuticals Inc up on Tuesday (MDP)

April 7, 2023 | theglobeandmail.com

Closing Bell: Medexus Pharmaceuticals Inc up on Thursday (MDP)

See More Headlines

Receive MDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: CVE
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: CVE:MDP
CUSIP: N/A
CIK: N/A
Web: www.medexus.com
Phone: 514-762-2626
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: C$3.18
High Stock Price Target: C$4.00
Low Stock Price Target: C$2.35
Potential Upside/Downside: -59.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: 9.23
P/E Growth: -2153
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 1,174.36
Current Ratio: 1.19
Quick Ratio: 0.74

Sales & Book Value

Annual Sales: C$108.29 million
Price / Sales: 1.37
Cash Flow: C$0.62 per share
Price / Cash Flow: 12.46
Book Value: C$0.38 per share
Price / Book: 20.50

Miscellaneous

Outstanding Shares: 19,167,000
Free Float: N/A
Market Cap: C$148.54 million
Optionable: Not Optionable
Beta: N/A

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Kenneth d'Entremont
CEO & Director
Mr. Roland Boivin
Chief Financial Officer
Mr. Bill Poncy
Sr. VP of Commercial Operations - United States
Mr. Brian Peters
VP of Sales & Marketing - United States
Ms. Tina Byers CFA
Exec. of Investor Relations
Mr. Michael Pine
Sr. VP of Bus. Devel. & Strategy
Mr. Michael David Adelman (Age 50)
Gen. Mang., U.S. Operations

Key Competitors

View All Competitors

Insiders

Benoit Gravel
Bought 3,200 shares on 2/13/2024
Total: C$5,408.00 ($1.69/share)

MDP Stock Analysis - Frequently Asked Questions

Should I buy or sell Medexus Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDP shares.
View MDP analyst ratings or view top-rated stocks.
What is Medexus Pharmaceuticals' stock price target for 2024?: 2 equities research analysts have issued 1 year price targets for Medexus Pharmaceuticals' stock. Their MDP share price targets range from C$2.35 to C$4.00. On average, they expect the company's stock price to reach C$3.18 in the next twelve months. This suggests that the stock has a possible downside of 59.0%.
View analysts price targets for MDP or view top-rated stocks among Wall Street analysts.
How have MDP shares performed in 2024?: Medexus Pharmaceuticals' stock was trading at C$7.75 at the beginning of 2024. Since then, MDP shares have increased by 0.0% and is now trading at C$7.75.
View the best growth stocks for 2024 here.

What other stocks do shareholders of Medexus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Medexus Pharmaceuticals investors own include Gatekeeper Systems (GSI), Enghouse Systems (ENGH), Ag Growth International (AFN).
How do I buy shares of Medexus Pharmaceuticals?: Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:MDP) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis